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“Caelum, non animum, mutant qui trans mare
currunt”
They change the sky, not their soul, who run across
the sea.
Horace, Epistles 1.11.27
In the wake of the United States’ regulations on the use
of
18F-fluorodeoxyglucose (FDG), the Spanish medicines
regulatory agency last year stated that the use of FDG with
PET, although well established in the areas of cancer,
cardiac medicine and neurology, is not yet sufficiently
established, within the European Union, in the diagnosis of
infectious and inflammatory diseases, and therefore should
not be authorised as a diagnostic radiopharmaceutical in
these conditions. This position was contested by other EU
member states and the dispute was eventually referred to
the European Medicines Agency (EMEA). The EMEA
Committee for Medicinal Products for Human Use (CHMP)
concluded that the benefits of FDG outweigh its risks, and
that its use should, therefore, be authorised across the EU.
The CHMP deemed adequately documented a series of
indications for the use of FDG in infectious or inflamma-
tory diseases, namely:
1. Localisation of abnormal foci to guide the aetiological
diagnosis in the presence of fever of unknown origin
(FUO)
2. Diagnosis of infection in: suspected chronic infection
of bone and/or adjacent structures (osteomyelitis,
spondylitis, discitis or osteitis including presence of
metallic implants), diabetes with suspicion of Charcot’s
neuroarthropathy, osteomyelitis and/or soft tissue in-
fection, painful hip prosthesis, vascular prosthesis, and
fever in AIDS
3. Detection of the extent of inflammation in: sarcoidosis,
inflammatory bowel disease, and vasculitis involving
the great vessels
4. Therapeutic follow-up of unresectable alveolar echino-
coccosis, in which it may be used in the search for
active localisations of the parasite during medical
treatment and after treatment discontinuation
However, although the use of FDG in infections has
EMEA approval, this approach still lacks the support of solid,
evidence-based criteria. In certain situations, it cannot yet be
considered an adequate replacement for labelled white blood
cell (WBC) imaging or anti-granulocytemonoclonal antibody
(MoAb) imaging. In this paper, we focus specifically on those
infectious and inflammatory diseases in which questions
remain over the use of FDG-PET as a tool for diagnostic
evaluation and treatment follow-up.
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For more than 20 years labelled leukocyte imaging using
99mTc-HMPAO or
111In-oxine has been the radionuclide
procedure of choice for diagnosing most infections, due to
the ability of radiolabelled granulocytes to migrate to the
foci of infection. Even years ago, high sensitivity and
specificity values were reported for this technique in
patients with FUO or a focal infection, while a negative
study virtually excludes an infection. Furthermore, if there
is a high suspicion of an infection, based on an increased
leukocyte count and on an elevated erythrocyte sedimenta-
tion rate and C-reactive protein level, this procedure
remains the diagnostic technique of choice, thus limiting
the use of
18F-FDG-PET/CT to cases of FUO with low
probability of infection. However, it is worth pointing out
that, to date, there exist no clearly established criteria for
determining probability of infection, and a consensus
statement would therefore be required.
FDG is a radiopharmaceutical that accumulates in
infections, malignancies and inflammatory diseases. This
non-specificity is extremely valuable in FUO, which is
caused, primarily, by these three conditions. The disadvan-
tage of FDG’s low specificity (lower than that of labelled
WBCs) is that it cannot always discriminate between
infection and neoplastic disease. Other disadvantages
are the considerable costs of FDG-PET and the fact
that PET facilities are still scarce in many developing
countries [1].
Several recent studies, retrospective and prospective,
have drawn attention to the added value of FDG-PET over
conventional techniques, recorded in 40–70% of patients
with FUO [2, 3]. Most studies also stress the technique’s
high negative predictive value in the assessment of FUO.
A recent study analysed the value of FDG-PET/CT in
children with FUO or unexplained signs of inflammation
without fever and found the technique to be a valuable
diagnostic tool in these subjects in whom a non-traumatic
method of depicting inflammation in the whole body is
obviously particularly useful [4]. The value of FDG-PET/CT
was also evaluated in critically ill, mechanically ventilated
patients suspected of having an infection or inflammatory
process. Comparisons of scans with clinical follow-up data
yielded overall accuracy of 91% and, on this basis, the
authors stated that FDG-PET/CT scanning is of additional
value in critically ill patients. A normal FDG-PET/CT scan
ruled out an infection requiring prolonged antibiotic therapy
or drainage [5]. In patients with human immunodeficiency
virus (HIV) and FUO, FDG-PET/CT emerged as a valuable
tool and was helpful for diagnosis, especially when CT
anatomical landmarks were added to PET findings [6].
All these studies stress the advantages of FDG-PET/CT
for evaluating patients with FUO. However, the studies
performed in this clinical setting in recent years are
weakened by the use of different definitions of FUO and
by the lack of a structured diagnostic protocol, which has
resulted in varying efficacy data [3].
For the time being, the probability of infection remains
the most useful criterion for choosing between FDG-PET/
CT and WBC imaging. In the presence of low and medium
probability FDG is the more indicated technique, whereas
WBC imaging should be performed when the probability of
infection is high. However, the body of evidence on the
utility of FDG-PET/CT in patients with FUO is growing
and this technique is probably destined to become the
preferred diagnostic procedure in the future, especially
when a definite diagnosis cannot easily be achieved.
Bone infections: osteomyelitis and spondylodiscitis
For acute osteomyelitis, WBC imaging combined—if
necessary—with bone marrow imaging or MoAb imaging,
is very reliable, with overall accuracy of approximately
90% [7]. FDG-PET/CT, used in combination with conven-
tional methods, may have limited value in the diagnosis of
uncomplicated cases of acute osteomyelitis; conversely, it
may play an important role in patients with chronic
osteomyelitis, particularly those with previously docu-
mented osteomyelitis and suspected recurrence, or present-
ing with symptoms of osteomyelitis for more than 6 weeks.
FDG-PET/CT can also be used to monitor response to
antimicrobial treatment and to develop criteria for deciding
when treatment can safely be stopped [3].
The performance of WBC imaging is poor in spondylitis
and spondylodiscitis: up to 50% of all patients with
spondylodiscitis show photopenic lesions due to encapsu-
lation of the infection, and therefore relatively hampered
migration of leukocytes; as a result the specificity of the
method is reduced [8]. In these patients, FDG-PET/CT gave
much better results: sensitivities ranging from 94% to 100%
and specificities ranging from 87% to 100%. In a recent
retrospective study, FDG-PET/CT had a strong impact on
the clinical management (initiation or prolongation of
antibiotic therapy or recourse to surgical intervention) of
52% of patients with infectious spondylitis [9]. A recent
review article highlights the clinical role of FDG-PET/CT
in diagnosing spinal infections, especially in patients with
contraindications to MRI, and in evaluation of the postop-
erative spine [10].
In summary, the use of FDG-PET/CT is clearly indicated
in spondylodiscitis (even though there is a need for clearer
criteria for positivity and for clarification of the role of the
standard uptake volume), whereas WBC and MoAb
imaging remain the gold standard imaging techniques in
patients with suspected osteomyelitis in peripheral bones.
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The role of WBC imaging in the diagnosis of diabetic pedal
osteomyelitis has been extensively investigated, disclosing
sensitivities—using
111In-oxine—ranging from 72% to
100% and specificities ranging from 67% to 100%. With
this approach, poor spatial resolution and lack of bony
landmarks makes the differentiation of soft tissue from
bone infection difficult; instead, much better results are
achieved using SPECT/CT [7]. FDG-PET/CT was found to
be highly sensitive in excluding osteomyelitis in the
diabetic foot, and to usefully complement MRI, particularly
in cases with positive MRI findings. Conventional imaging
like MRI or bone scanning, also lacks specificity as a means
of distinguishing osteomyelitis in the diabetic foot from
Charcot’s neuroarthropathy. Preliminary data suggest that
FDG-PET/CTcould play a role in assessing complicated and
uncomplicated diabetic osteoarthropathy, being able to
provide accurate assessment of patients with metal implants
who may not be suitable candidates for MRI, and to
correctly distinguish osteomyelitis from neuroarthropathy
[3]. In a recent prospective study conducted in 110 patients
with complicated diabetic foot, FDG-PET/CT was found to
be a highly specific imaging modality for the diagnosis of
osteomyelitis and was deemed a useful complementary
imaging modality for use with MRI [11].
However, our group recently investigated the role of
FDG-PET/CT in the diabetic foot and found—even with
sequential imaging—low overall diagnostic accuracy.
These findings suggest that FDG-PET/CT cannot yet
replace WBC imaging, particularly when WBC is acquired
using SPECT/CT modality and bone marrow imaging is
added for Charcot’s foot.
Hip and knee prosthesis infections
WBC imaging—if necessary combined with bone marrow
imaging—is currently the radionuclide imaging procedure
of choice for diagnosing prosthetic joint infections, on
account of its almost 90% accuracy [12]. MoAb imaging
also shows very high accuracy, thus limiting the need for
alternative modalities. Theoretically, FDG-PET/CT has the
potential to detect infection in hip and, to a lesser extent,
knee prostheses. It is not affected by artefacts due to metal
implants and it provides images with higher resolution than
those produced using conventional nuclear medicine tech-
niques. However, non-infectious reactions around the neck
of the prosthesis are common months and even years after
surgery, and these may influence the diagnosis. Increased
FDG uptake around the neck and/or head should not be
interpreted as a finding suggestive of infection. Studies in
the past that compared WBC imaging with FDG-PET
scanning in prosthetic joint infections showed better results
with WBC imaging, which proved more sensitive and more
specific than FDG-PET. The lack of specificity of the FDG-
PET/CT modality prompted definition of interpretation
criteria [8]. To date, WBC/MoAb imaging remains the
gold standard technique for evaluating prosthetic infections
and the question of whether FDG-PET/CT can provide
satisfactory diagnostic accuracy in these patients is still
debated. If well-designed prospective studies prove able to
establish criteria for infection and aseptic loosening, it is
possible that there may, in the future, be a role for FDG-
PET/CT in the evaluation of prosthetic joint infections.
Vascular graft infections
Vascular graft infections are uncommon but severe compli-
cations that can occur long after surgery. Sensitivities of
WBC imaging for diagnosing graft infections range from
53% to 100%, and specificities from 50% to 100%. False-
positive results are often reported and have been associated
with perigraft haematomas, thrombosed grafts, bleeding
and recent surgery. There is little literature regarding the
role of FDG-PET/CT in the assessment of vascular graft
infections, but that which is available suggests that this
modality is a reliable tool in this clinical setting and also
indicates that CT is mandatory for the correct localisation of
FDG accumulation [13]. Indeed it is not uncommon for
FDG-PET/CT to detect infection of vascular grafts even
when the angio-CT results are negative; in the past,
comparison of the two modalities showed FDG-PET to be
superior to CT scanning alone. Combining FDG-PET with
CT increases the test specificity and therefore the diagnostic
accuracy because the precise anatomical localisation of
increased FDG uptake, thanks to PET/CT, allows accurate
differentiation between graft and adjacent soft tissue
infection, leading to more accurate diagnosis and thus an
optimal therapeutic strategy. This added value of PET/CT
over PET alone has been described by several investigators.
In particular, Spacek et al., prospectively evaluating FDG-
PET/CT in 76 patients with a total of 96 vascular prosthetic
grafts, found the technique to be reliable, having an
accuracy of >95% in 75% of the prostheses (the ones with
intense uptake) [14]. These authors’ interesting attempt to
identify interpretation criteria in order to increase the
diagnostic accuracy of FDG-PET/CT is an endeavour that
others would do well to emulate. Again it emerges that
interpretation criteria (qualitative versus quantitative) are
mandatory and require multi-centre validation.
In general, it is agreed that FDG-PET/CT is the modality
of choice in vascular graft prosthesis. Menezes et al.
examined the question of the ideal imaging time in 17
patients with atherosclerotic abdominal aorta aneurysms
1988 Eur J Nucl Med Mol Imaging (2010) 37:1986–1991and found no significant differences between imaging at 1 h
and 3 h after injection [15]. Similar findings have been
recorded in osteomyelitis and FUO.
Vasculitis
As regards the use of FDG-PET/CT in the evaluation of
large-vessel vasculitis, a few brief comments suffice. The
modality has proven validity in this setting, with sensitivity
values ranging from 77% to 92% and specificities ranging
from 89% to 100%. FDG-PET/CT has proven utility in the
initial diagnosis of patients suspected of having vasculitis,
particularly those who present with non-specific symptoms,
in the identification of areas of increased FDG uptake
requiring biopsy, and in the evaluation of the extent of
disease [16].
Evaluation of therapy in infectious or inflammatory
diseases
The CHMP report mentions the use of FDG-PET/CT in
treatment evaluation only in connection with unresectable
alveolar echinococcosis. Despite this lack of attention, it is
our view that FDG-PET/CT could play a pivotal role in
therapy assessment. The evolution of FDG uptake reflects
the efficacy of the medical treatment, and its careful
assessment can lead to better modulation of the drug
dosage or prompt a radical modification of the therapeutic
strategy. It has been shown to be a valuable imaging tool
for assessing treatment efficacy in systemic sarcoidosis,
large-vessel arteritis, tuberculosis and aspergillosis [17]. In
vasculitis, FDG-PET/CT also has proven utility in assessing
response to therapy [16]. From this perspective, it is
possible to conceive of a role for FDG-PET/CT in
monitoring therapy response and early relapses of inflam-
matory bowel diseases, even though only limited data are
currently available in this regard [18]. As regards the
monitoring of antibiotic therapy in osteomyelitis, there is,
as yet, no published evidence to support this indication.
AIDS and tuberculosis
We have already discussed the role of FDG-PET/CT in
patients with HIV and FUO [6]. However, FDG-PET also
plays a major role in the assessment and management of
HIV-1-infected patients [3]. FDG-PET data have shown
that HIV-1 infection progresses by distinct anatomical
steps, with involvement of the upper torso preceding
involvement of the lower part of the body, and that the
degree of FDG uptake is related to viral load [19]. FDG
uptake by the lymph nodes of HIV-positive patients was
found to be inversely related to CD4 count, thereby
supporting the theory of CD4 cell depletion through forced
lymph node homing [20]. In the clinical setting, FDG-PET
has been shown to allow the differentiation of AIDS-related
opportunistic infections and malignancies, and to allow
monitoring of the side effects of highly active antiretroviral
treatment [21]. Comparison of FDG uptake in patients who
had received antiretroviral therapy (ART) and patients who
were ART-naïve revealed different patterns of FDG uptake:
all the ART-treated patients with either suppressed or high
viraemia showed a normal pattern, while the ART-naïve
patients with high viraemia displayed multiple foci of
increased glucose metabolism in the lymph nodes. Togeth-
er, this finding and the finding of a correlation between the
well-established markers of progression to AIDS and
positive FDG-PET in ART-naïve patients seem to confer
prognostic value on FDG uptake [22].
Data on FDG-PET imaging in patients suffering from
tuberculosis (TB) are very limited. Pulmonary TB com-
monly causes an increase in FDG uptake, whereas uptake is
low in tuberculous pleural effusion. Sites of extra-
pulmonary TB can be detected with FDG-PET, including
disease involving the central nervous system and joint and
bone TB [23].
In general, it is difficult in patients with high FDG
uptake to differentiate between a malignancy, HIV infection
and TB. Several authors have shown that FDG uptake
continues to increase over time in malignant lesions,
whereas in inflammatory lesions uptake decreases or
remains stable. However, studies conducted to assess the
potential impact of double-phase FDG-PET versus routine
staging in patients suffering from TB confirmed that it is
extremely difficult to distinguish TB from malignant
involvement [24]. This was also borne out by the findings
of a study in HIV-infected children, in whom FDG-PET
scanning proved unable to discriminate reliably between
malignant and inflammatory pathology [25].
However, differentiation between malignancies, AIDS
and TB is extremely important. In patients with HIV and
TB, early identification and diagnosis are the keys to
effective control of the disease. Correct identification of TB
is crucially important in order to start anti-TB treatment and
delay antiretroviral treatment for HIV. The presentation of
TB in the HIV-infected patient is different from that
observed in the HIV-negative patient: apical predominance
is less pronounced, while consolidation, cavitations and
haematogenic disseminations are less prevalent. In this
context, FDG-PET/CT may aid in the diagnosis.
Aggressive lymphoid proliferations should be differenti-
ated from generalised lymphadenopathy, which does not
have a negative outcome, and here again FDG-PET may
play a central role. FDG-PET scanning could also be
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FDG activity may also be a useful tool for evaluating and
excluding sites of active disease in the context of targeted
screening for latent TB infection before immunosuppres-
sive treatment.
Finally, a new strategy for the application of FDG-PET/
CT in AIDS patients needs to be put in place and would
certainly prove beneficial in the management of opportu-
nistic infections (TB), facilitating diagnosis and improving
response to therapy.
Conclusions and future perspectives
Over the past decade, FDG-PET/CT has emerged as a
rapidly evolving diagnostic tool in infectious diseases. Its
clinical impact on diagnosis, staging and evaluation of
therapy, already high, is destined to increase in the
future. However, FDG-PET/CT is not always the best
radionuclide imaging technique to choose in the presence
of infectious diseases. The value of WBC/MoAb scan-
ning in different infectious diseases has been well
established over the past 20 years and should not be
overlooked. Larger prospective studies evaluating the
role of FDG-PET/CT in the clinical management of
patients with infectious diseases are needed, and in many
cases it remains to be seen whether this modality will
prove able to record the high sensitivity and specificity
values already shown by WBC/MoAb imaging.
In many inflammatory conditions there is also a pressing
need to develop clear criteria for interpreting FDG-PET/CT.
In an attempt to combine the best of both worlds,
leukocytes were labelled with
18F-FDG. Although promis-
ing preliminary results were obtained, FDG was found to be
rapidly released from the labelled leukocytes. Further major
drawbacks were the labelling time, the short half-life of the
tracer, the costs, and the need for specific expertise [1]. Yet
this is far from the end of the road for leukocyte PET/CT
imaging: the common clinical need for specific and
anatomically precise detection of infection, the availability
of the components necessary for performing leukocyte
PET/CT, and their lack of toxicity and adverse effects are
all factors making it worthwhile to go on exploring the
scope for PET/CT imaging, in larger prospective studies
[26]. In this context, the ongoing quest to find better
labelling agents may well result in the identification of the
ideal PET/CT radiopharmaceutical for imaging infection
and inflammation.
“Caelum, non animum, mutant qui trans mare
currunt”: while we may change technique and/or radio-
pharmaceutical, we nevertheless remain steadfast in our
determination to achieve diagnostically accurate imaging of
infection.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Signore A, Soroa VA, De Vries EF. Radiobelled white blood cells
or FDG for imaging on inflammation and infection? Q J Nucl
Med Mol Imaging. 2009;53(1):23–5.
2. Balink H, Collins J, Bruyn G, Gemmel F. F-18 FDG PET/CT in
the diagnosis of fever of unknown origin. Clin Nucl Med. 2009;34
(12):862–8.
3. Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA,
Alavi A. Positron emission tomography as a diagnostic tool in
infection: present role and future possibilities. Semin Nucl Med.
2009;39(1):36–51.
4. Jasper N, Däbritz J, Frosch M, Loeffler M, Weckesser M, Foell D.
Diagnostic value of [(18)F]-FDG PET/CT in children with fever
of unknown origin or unexplained signs of inflammation. Eur J
Nucl Med Mol Imaging. 2010;37(1):136–45.
5. Simons KS, Pickkers P, Bleeker-Rovers CP, Oyen WJ, van der
Hoeven JG. F-18-fluorodeoxyglucose positron emission tomogra-
phy combined with CT in critically ill patients with suspected
infection. Intensive Care Med. 2010;36(3):504–11.
6. Castaigne C, Tondeur M, de Wit S, Hildebrand M, Clumeck N,
Dusart M. Clinical value of FDG-PET/CT for the diagnosis of
human immunodeficiency virus-associated fever of unknown
origin: a retrospective study. Nucl Med Commun. 2009;30
(1):41–7.
7. Palestro CJ, Love C, Bhargava KK. Labeled leukocyte imaging:
current status and future directions. Q J Nucl Med Mol Imaging.
2009;53(1):105–23.
8. van der Bruggen W, Bleeker-Rovers CP, Boerman OC, Gotthardt M,
Oyen WJ. PETand SPECTin osteomyelitis and prosthetic bone and
joint infections: a systematic review. Semin Nucl Med. 2010;40
(1):3–15.
9. Ito K, Kubota K, Morooka M, Hasuo K, Kuroki H, Mimori A.
Clinical impact of 18F-FDG PET/CT on the management and
diagnosis of infectious spondylitis. Nucl Med Commun. 2010;31
(8):691–8.
1 0 .G e m m e lF ,R i j kP C ,C o l l i n sJ M ,P a r l e v l i e tT ,S t u m p eK D ,
Palestro CJ. Expanding role of 18F-fluoro-D-deoxyglucose
PET and PET/CT in spinal infections. Eur Spine J. 2010;19
(4):540–51.
11. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T,
Alavi A. Diagnostic performance of FDG-PET, MRI, and plain
film radiography (PFR) for the diagnosis of osteomyelitis in the
diabetic foot. Mol Imaging Biol. 2010;12(3):335–42.
12. Love C, Marwin SE, Palestro CJ. Nuclear medicine and the
infected joint replacement. Semin Nucl Med. 2009;39(1):66–78.
13. Keidar Z, Nitecki S. FDG-PET for the detection of infected
vascular grafts. Q J Nucl Med Mol Imaging. 2009;53(1):35–40.
14. Spacek M, Belohlavek O, Votrubova J, Sebesta P, Stadler P.
Diagnostics of “non-acute” vascular prosthesis infection using
18F-FDG PET/CT: our experience with 96 prostheses. Eur J Nucl
Med Mol Imaging. 2009;36(5):850–8.
15. Menezes LJ, Kotze CW, Hutton BF, Endozo R, Dickson JC,
Cullum I, et al. Vascular inflammation imaging with 18F-FDG
PET/CT: when to image? J Nucl Med. 2009;50(6):854–7.
16. Zerizer I, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, et
al. Role of FDG-PET and PET/CT in the diagnosis and
management of vasculitis. Eur J Radiol. 2010;73(3):504–9.
1990 Eur J Nucl Med Mol Imaging (2010) 37:1986–199117. Imperiale A, Federici L, Lefebvre N, Braun JJ, Pfumio F, Kessler R,
et al. F-18 FDG PET/CT as a valuable imaging tool for assessing
treatmentefficacyininflammatory andinfectiousdiseases.ClinNucl
Med. 2010;35:86–90.
18. Glaudemans AW, Maccioni F, Mansi L, Dierckx RA, Signore A.
Imaging of cell trafficking in Crohn’s disease. J Cell Physiol.
2010;223(3):562–71.
19. Sathekge M, Goethals I, Maes A, Van de Wiele C. Positron
emission tomography in patients suffering from HIV-1 infection.
Eur J Nucl Med Mol Imaging. 2009;36(7):1176–84.
20. Sathekge M, Maes A, Kgomo M, Van de Wiele C. Fluorodeox-
yglucose uptake by lymph nodes of HIV patients is inversely related
to CD4 cell count. Nucl Med Commun. 2010;31(2):137–40.
21. Sathekge M, Goethals I, Maes A, Van de Wiele C. Positron
emission tomography in patients suffering from HIV-1 infection.
Eur J Nucl Med Mol Imaging. 2009;36(7):1176–84.
22. Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G,
et al. FDG-PET imaging in HIV-infected subjects: relation with
therapy and immunovirological variables. Eur J Nucl Med Mol
Imaging. 2009;36(4):640–7.
23. Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, Van de Wiele
C. Impact of FDG PET on the management of TBC treatment. A
pilot study. Nuklearmedizin. 2010;49(1):35–40.
24. Hadley GP, Naude F. Malignant solid tumour, HIV infection and
tuberculosis in children: an unholy triad. Pediatr Surg Int. 2009;25
(8):697–701.
25. Sathekge M, Maes A, Al Nahhas A, Rubello D, Chiti A. What
impact can fluorine-18 fluorodeoxyglucose PET/computed to-
mography have on HIV/AIDS and tuberculosis pandemic? Nucl
Med Commun. 2009;30(4):255–7.
26. Dumarey N. Imaging with FDG labeled leukocytes: is it clinically
useful? Q J Nucl Med Mol Imaging. 2009;53(1):89–94.
Eur J Nucl Med Mol Imaging (2010) 37:1986–1991 1991